Biblio
Export 309 results:
Author Title Type [ Year] Filters: First Letter Of Keyword is T [Clear All Filters]
“18F-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy.”, J Alzheimers Dis, vol. 57, no. 3, pp. 711-716, 2017.
, “Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.”, J Alzheimers Dis, vol. 57, no. 3, pp. 683-696, 2017.
, “Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.”, J Alzheimers Dis, vol. 57, no. 3, pp. 765-773, 2017.
, “Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1285-1294, 2017.
, “Low Florbetapir PET Uptake and Normal Aβ1-42 Cerebrospinal Fluid in an APP Ala713Thr Mutation Carrier.”, J Alzheimers Dis, vol. 57, no. 3, pp. 697-703, 2017.
, “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
, “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
, “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
, “PCSK9 Promotes oxLDL-Induced PC12 Cell Apoptosis Through the Bcl-2/Bax-Caspase 9/3 Signaling Pathway.”, J Alzheimers Dis, vol. 57, no. 3, pp. 723-734, 2017.
, “The Progression of Alzheimer's Disease: Are Fast Decliners Really Fast? A Four-Year Follow-Up.”, J Alzheimers Dis, vol. 57, no. 3, pp. 775-786, 2017.
, “Role of Suppressor of Cytokine Signaling 3 (SOCS3) in Altering Activated Microglia Phenotype in APPswe/PS1dE9 Mice.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1235-1247, 2017.
, “Sleep Deprivation Induced Plasma Amyloid-β Transport Disturbance in Healthy Young Adults.”, J Alzheimers Dis, vol. 57, no. 3, pp. 899-906, 2017.
, “Activation of p53 in Down Syndrome and in the Ts65Dn Mouse Brain is Associated with a Pro-Apoptotic Phenotype.”, J Alzheimers Dis, vol. 52, no. 1, pp. 359-71, 2016.
, “Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).”, J Alzheimers Dis, vol. 49, no. 2, pp. 287-300, 2016.
, “Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid-β Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD).”, J Alzheimers Dis, vol. 49, no. 2, pp. 287-300, 2016.
, “Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid.”, J Alzheimers Dis, vol. 49, no. 3, pp. 829-44, 2016.
, “Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid.”, J Alzheimers Dis, vol. 49, no. 3, pp. 829-44, 2016.
, “Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1085-97, 2016.
, “Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI.”, J Alzheimers Dis, vol. 51, no. 1, pp. 227-36, 2016.
, “Association Between Serum Ceruloplasmin Specific Activity and Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1181-9, 2016.
, “Beneficial Effects of an Integrated Psychostimulation Program in Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 2, pp. 559-66, 2016.
, “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.
, “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
, “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
, “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
,